"Further, the potential short- and long-term risks to the breastfeeding infant have been insufficiently studied," the authors noted
For us, GLP-1s, last year, were number 32, and this year theyre number one [in pharmacy spending]. Human Resources Director, health benefits administrator Before we knew it, we spent half a million dollars and were projected to go up to $1.2 million the following year. Manager of Compensation and Benefits Administration, large retail firm Ill just say our GLP-1 agonist spending year over year was increasing 50% for weight loss
Xi L, Brown K, Woodworth J, Shim K, Johnson B, Odle J
Dietary patterns and management of type 2 diabetes: A systematic review of randomised clinical trials
Holds LegitScript certification and emphasizes trust, transparency, and patient education
Joly F, Seguy D, Nuzzo A, Chambrier C, Beau P, Poullenot F, et al